Earnings summaries and quarterly performance for biote.
Executive leadership at biote.
Board of directors at biote.
Research analysts who have asked questions during biote earnings calls.
JV
Jeff Van Sinderen
B. Riley Securities
6 questions for BTMD
Also covers: BYRN, CDRE, CELH +12 more
GK
George Kelly
ROTH Capital Partners
5 questions for BTMD
Also covers: BODI, BRCC, CSV +11 more
LS
Leszek Sulewski
Truist Securities
4 questions for BTMD
Also covers: AKBA, AMRX, ANIP +6 more
KK
Kaitlyn Korich
Jefferies
3 questions for BTMD
Jeevan Larson
Truist Securities
2 questions for BTMD
Also covers: ANIP, COLL, CRMD
JK
Jungwon Kim
BTIG, LLC
2 questions for BTMD
Also covers: BBWI, JILL, OLPX +2 more
Kaumil Gajrawala
Jefferies
2 questions for BTMD
Also covers: BARK, BGS, BRBR +23 more
AF
Alex Fuhrman
Craig-Hallum Capital Group LLC
1 question for BTMD
Also covers: APYX, ATER, BNED +23 more
JK
Jonna Kim
TD Cowen
1 question for BTMD
Also covers: AEO, AKA, BBWI +8 more
Recent press releases and 8-K filings for BTMD.
Biote Reports Q4 2025 Results and Provides 2026 Outlook
BTMD
Earnings
Guidance Update
New Projects/Investments
- Biote reported Q4 2025 revenue of $46.4 million, a 6.9% decrease year-over-year, with procedure revenue declining 13% to $31.8 million and dietary supplement revenue growing 16% to $11.7 million.
- For Q4 2025, net income was $2.6 million and diluted EPS was $0.06, while Adjusted EBITDA decreased to $11.7 million with a 25.2% margin. The gross profit margin of 68.0% was impacted by a $1.3 million charge to inventory due to a voluntary recall of hormone pellets.
- For 2026, Biote forecasts revenues above $190 million and adjusted EBITDA greater than $38 million. Procedure revenue is expected to decrease in the first half of 2026 but return to year-on-year growth in the second half.
- The company plans significant investments in 2026, including expanding its sales personnel from over 90 to approximately 120 and investing in its technology platform, which will impact adjusted EBITDA. These investments are aimed at accelerating growth and enhancing practitioner engagement.
2 days ago
Biote Reports Q4 2025 Results, Provides 2026 Outlook, and Details Strategic Investments
BTMD
Earnings
Guidance Update
New Projects/Investments
- Biote reported Q4 2025 revenue of $46.4 million, a 6.9% decrease year-over-year, with procedure revenue declining 13% to $31.8 million and dietary supplement revenue growing 16% to $11.7 million.
- For Q4 2025, net income was $2.6 million and diluted EPS was $0.06, while Adjusted EBITDA decreased to $11.7 million with a 25.2% margin.
- The company provided 2026 guidance, projecting total revenue above $190 million and Adjusted EBITDA greater than $38 million.
- Biote plans substantial investments in 2026 to expand its sales force to approximately 120 personnel and enhance its technology platform, which are expected to impact near-term operating expenses but drive procedure revenue growth in the second half of 2026.
- A voluntary recall of hormone pellets led to a $1.3 million inventory charge in Q4 2025, impacting gross margin, and procedure revenue is anticipated to decline in the first half of 2026 due to higher attrition and the recall's potential impact.
2 days ago
Biote Reports Q4 2025 Results and Provides 2026 Outlook
BTMD
Earnings
Guidance Update
New Projects/Investments
- Biote reported Q4 2025 revenue of $46.4 million, a 6.9% decrease year-over-year, with procedure revenue declining 13% to $31.8 million, while dietary supplement revenue grew 16% to $11.7 million.
- Adjusted EBITDA for Q4 2025 was $11.7 million, down from $15.1 million in Q4 2024, with the gross profit margin impacted by a $1.3 million charge due to a voluntary recall of hormone pellets.
- For 2026, Biote forecasts revenues above $190 million and adjusted EBITDA greater than $38 million, anticipating a mid- to high-single-digit percentage decrease in procedure revenue in the first half, followed by a return to year-on-year growth in the second half.
- The company plans significant investments in 2026, expanding its sales personnel from over 90 to approximately 120 and enhancing its technology platform, which will increase operating expenses and impact adjusted EBITDA in the near term.
- Biote noted an acceleration in the number of practitioners attending trainings, with all sessions at full capacity, and signs of stabilizing clinic attrition, which had accelerated to high single digits in 2024.
2 days ago
biote Corp. Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Outlook
BTMD
Earnings
Guidance Update
Demand Weakening
- biote Corp. reported Q4 2025 revenue of $46.4 million and full-year 2025 revenue of $192.2 million, representing a 6.9% decrease for Q4 and a 2.5% decrease for the full year compared to 2024.
- Net income for Q4 2025 was $2.6 million (diluted EPS of $0.06) and $31.6 million (diluted EPS of $0.74) for the full year 2025.
- Adjusted EBITDA was $11.7 million for Q4 2025 and $53.5 million for the full year 2025.
- The company anticipates a return to procedure revenue growth in the second half of 2026, following an expected decrease in the first half of 2026.
- For 2026, biote Corp. projects revenue above $190 million and Adjusted EBITDA above $38 million.
2 days ago
Biote Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
BTMD
Earnings
Guidance Update
Demand Weakening
- Biote reported Q4 2025 revenue of $46.4 million and full-year 2025 revenue of $192.2 million.
- For the full year 2025, net income significantly increased to $31.6 million ($0.74 diluted EPS) compared to $0.05 million ($0.09 diluted EPS) in 2024.
- The company provided 2026 guidance, anticipating revenue above $190 million and Adjusted EBITDA above $38 million.
- Biote expects a return to procedure revenue growth in the second half of 2026, following an anticipated decrease in the first half of the year.
2 days ago
biote Corp. Announces Voluntary Recall of Hormone Pellets
BTMD
Legal Proceedings
Profit Warning
- biote Corp. subsidiary, Asteria Health, initiated a voluntary recall of specific lots of hormone pellets due to the potential presence of metal particulate matter.
- The recall impacts products shipped between May 20, 2025, and January 19, 2026, and is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).
- The company anticipates a one-time charge of approximately $1.3 million to its fourth quarter 2025 cost of products for inventory write-off, with an additional estimated $1.0 million in recall-related costs in 2026.
- biote Corp. does not believe its fourth quarter business was impacted beyond the inventory write-off and does not anticipate a material impact on its ability to provide pellets or for practitioners to service patients.
Jan 26, 2026, 10:21 PM
Biote Reports Q3 2025 Financial Results and Reaffirms Full-Year Guidance
BTMD
Earnings
Guidance Update
Share Buyback
- Biote reported Q3 2025 revenue of $48.0 million, a 6.7% decrease year-over-year, primarily due to a 10.4% decline in procedure revenue, while dietary supplements revenue grew 8.4% to $11.2 million.
- For Q3 2025, net income was $9.2 million and diluted EPS was $0.22; adjusted EBITDA decreased 20.5% to $12.9 million, resulting in an adjusted EBITDA margin of 26.9%.
- The company reiterated its fiscal 2025 guidance for revenue above $190 million and adjusted EBITDA above $50 million.
- Biote repurchased approximately 1 million shares of Class A common stock at an average price of $3.28 per share and amended settlement agreements with Marcy and Dr. Gary Donovitz, achieving cash flow savings of approximately $7.5 million and $11.1 million, respectively.
- The commercial team is currently at 75-80% of its planned sales rep headcount for 2025, and the attrition rate remained elevated at around 8% in Q3, similar to Q2.
Nov 5, 2025, 10:00 PM
Biote Corp. Reports Third Quarter 2025 Financial Results and Reiterates 2025 Guidance
BTMD
Earnings
Guidance Update
Share Buyback
- Biote Corp. reported Q3 2025 revenue of $48.0 million, a 6.7% decrease from the prior year, with net income of $9.2 million and diluted earnings per share of $0.22.
- Adjusted EBITDA for Q3 2025 was $12.9 million, a 20.5% decrease from the prior year, resulting in an Adjusted EBITDA margin of 26.9%.
- The company reiterated its 2025 financial guidance, projecting revenue above $190 million and Adjusted EBITDA above $50 million.
- During the third quarter of 2025, Biote repurchased approximately one million shares of Class A common stock.
Nov 5, 2025, 9:08 PM
Biote Reports Third Quarter 2025 Financial Results
BTMD
Earnings
Guidance Update
Share Buyback
- Biote reported revenue of $48.0 million, net income of $9.2 million, and diluted earnings per share of $0.22 for the third quarter ended September 30, 2025.
- The company's gross profit margin improved to 71.8%, and Adjusted EBITDA was $12.9 million for the quarter.
- Biote repurchased approximately one million shares of Class A common stock in the third quarter and reiterated its 2025 financial guidance, forecasting revenue above $190 million and Adjusted EBITDA above $50 million.
- The company also amended settlement agreements to repurchase remaining shares from Marci Donovitz for $12.5 million (paid in October 2025) and Dr. Gary Donovitz for $18.5 million (to be paid in January 2026).
Nov 5, 2025, 9:05 PM
Biote Corp Announces Q1 2025 Results and Strategic Restructuring
BTMD
Earnings
Revenue Acceleration/Inflection
Guidance Update
Layoffs
- Q1 2025 revenue increased 4.7% to $49.0M with a gross margin of 74.3%
- Net income improved to $15.8M with a diluted EPS of $0.37, reversing last year's net loss
- Reaffirmed full-year guidance at $202M–$208M in revenue and $59M–$64M in adjusted EBITDA
- Dietary supplements grew 25.5%, while procedure revenue declined 3.6%
- Announced a strategic organizational restructuring to drive enhanced clinic growth and operational efficiency, including a 25% expansion in its field sales force
- Anticipated Q2 restructuring charges of $0.6–$0.8M, with an additional minor charge expected
May 7, 2025, 9:01 PM
Quarterly earnings call transcripts for biote.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more